These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 4096253)

  • 41. [Stability of antilipidemic etofibrate and its metabolites towards gastrointestinal and blood hydrolases (author's transl)].
    Oelschläger H; Rothley D; Ewert M; Nachev P
    Arzneimittelforschung; 1980; 30(6):984-8. PubMed ID: 7191278
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Plafibride (ITA 104).
    Arzneimittelforschung; 1981; 31(10a):1781-866. PubMed ID: 7198454
    [No Abstract]   [Full Text] [Related]  

  • 43. Effect of the hypolipidemic drug bezafibrate on the hepatic mixed function oxidase system of the rat: heterogeneity monooxygenase responses.
    Facino RM; Carini M
    Pharmacol Res Commun; 1981 Oct; 13(9):861-71. PubMed ID: 7335763
    [No Abstract]   [Full Text] [Related]  

  • 44. [Peroxisome induction with clofibric acid and bis(p-chlorophenoxy)acetic acid (proceedings)].
    Zipper J; Janowski K; Göres E
    Pharmazie; 1979; 34(5-6):366-7. PubMed ID: 515158
    [No Abstract]   [Full Text] [Related]  

  • 45. [Pharmacokinetic study in man of hypolipemic agents derived from clofibric acid after single and repeated administration].
    Cailleux A; Allain P; Tadei A
    Therapie; 1976; 31(5):637-45. PubMed ID: 1013956
    [No Abstract]   [Full Text] [Related]  

  • 46. [Serum gas chromatographic determination of hypolipemic agents derived from clofibric acid].
    Cailleux A; Allain P
    Therapie; 1976; 31(5):631-6. PubMed ID: 1013955
    [No Abstract]   [Full Text] [Related]  

  • 47. Effects of clofibric acid and bezafibrate administration on activities of alkaline phosphatase and other enzymes in livers of rats.
    Walli AK; Seidel D
    Res Exp Med (Berl); 1981; 179(2):153-61. PubMed ID: 7280363
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Carbohydrate metabolism in bezafibrate therapy. Controlled study of glibenclamide-treated diabetics with hyperlipidemia].
    Janka HU; Standl A; Holler HD; Mehnert H
    MMW Munch Med Wochenschr; 1982 May; 124(21):535-7. PubMed ID: 6810123
    [No Abstract]   [Full Text] [Related]  

  • 49. [Efficacy of bezafibrate and fenofibrate on elevated blood lipids in HLP type IIa, IIb and IV].
    Schwartzkopff W; Luley C; Scheffler W; Lehmann-Leo W; Schilling A; Wegscheider K
    Med Welt; 1982 Apr; 33(17):631-7. PubMed ID: 7098826
    [No Abstract]   [Full Text] [Related]  

  • 50. [The action of a fibric acid derivative on lipid metabolism].
    Filip M; Păduraru I; Nechifor M; Dănilă GH; Popovici I; Filip FM; Poşircă F
    Rev Med Chir Soc Med Nat Iasi; 1989; 93(3):573-6. PubMed ID: 2636755
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enantiomers of clofibric acid analogs have opposite actions on rat skeletal muscle chloride channels.
    Conte-Camerino D; Mambrini M; DeLuca A; Tricarico D; Bryant SH; Tortorella V; Bettoni G
    Pflugers Arch; 1988 Nov; 413(1):105-7. PubMed ID: 2464159
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhibitory effect of antioxidants ethoxyquin and 2(3)-tert-butyl-4-hydroxyanisole on hepatic tumorigenesis in rats fed ciprofibrate, a peroxisome proliferator.
    Rao MS; Lalwani ND; Watanabe TK; Reddy JK
    Cancer Res; 1984 Mar; 44(3):1072-6. PubMed ID: 6692393
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Experimental pharmacological study of moroxybrate, a hypolipidaemic, antithrombotic, antiatheromatous agent.
    Moreau P; Jacotot B; Tillement JP
    J Pharm Pharmacol; 1987 Jan; 39(1):35-8. PubMed ID: 2880981
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metabolic effects of a new hypolipidemic agent, ciprofibrate.
    Arnold A; McAuliff MP; Beyler AL
    J Pharm Sci; 1979 Dec; 68(12):1557-8. PubMed ID: 529054
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The pharmacokinetics of hypolipemic agents. 6. Is 2-(4-(2,2-dichlorocyclopropyl)-phenoxy)-propane a metabolite of the hypolipemic ciprofibrate?].
    Oelschläger H; Rothley D; Hellwich KH; Schmidt W
    Arch Pharm (Weinheim); 1989 Oct; 322(10):629-32. PubMed ID: 2624522
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Metabolism and pharmacokinetics of etofylline clofibrate, new antilipemic].
    Lücker PW; Wetzelsberger K; Erking W; Donike M
    Arzneimittelforschung; 1980; 30(11b):2045-53. PubMed ID: 7194058
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Atherosclerosis treatment with etofibrate retard. New perspectives].
    Degenring FH; Schatton W; Hotz W
    Fortschr Med; 1983 Aug; 101(30):1391-6. PubMed ID: 6618402
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical trials of plafibride in geriatric patients.
    Demichelis Genesio MA; Bracons R; Vicens B; Zapatero J; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1852-5. PubMed ID: 7198465
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Toxicological studies of plafibride. Part 2: Subacute and subchronic toxicity in rats and chronic toxicity in dogs.
    Zapatero J; Sanfeliu C; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1819-30. PubMed ID: 7198459
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The antilipemic effectiveness of aluminium clofibrate on hyperlipidemic patients with or without diabetes mellitus.
    Lam HC; Li SH; Wang JT; Tang KT; Ho LT
    Zhonghua Yi Xue Za Zhi (Taipei); 1987 Nov; 40(5):463-70. PubMed ID: 3332236
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.